Author： Sheean Geoffrey
Publisher： Adis International
ISSN： 0114-5916
Source： Drug Safety, Vol.29, Iss.1, 2006-01, pp. : 31-48
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
A Benefit-Risk Assessment of Baclofen in Severe Spinal Spasticity
By Alessandro Dario Giustino Tomei
Drug Safety, Vol. 27, Iss. 11, 2004-01 ,pp. :
Access to resources
Recommend
Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer
Drug Safety, Vol. 35, Iss. 1, 2012-01 ,pp. :
Benefit-Risk Assessment of Levetiracetam in the Treatment of Partial Seizures
Drug Safety, Vol. 28, Iss. 10, 2005-01 ,pp. :
Benefit-Risk Assessment of Infliximab in the Treatment of Rheumatoid Arthritis
By Mikuls T.R.
Drug Safety, Vol. 26, Iss. 1, 2003-01 ,pp. :